Silicon Laboratories Interim Filing: Revenue Up, Loss on Every Earnings Line

Bottom line

For the three-month and six-month reporting windows covered by 10-Q for period-ended-2026-07-04 of SILICON LABORATORIES INC. (CIK 0001038074, accession 0001038074-26-000029, ticker SLAB), every profitability line landed in negative territory, while top-line revenue registered positive on both windows. The reported snapshot is therefore a "revenue up, loss on every earnings line" pattern, not a turnaround.

- Reported three-month revenue ($228,189,000) was higher than the prior-year three-month figure ($192,845,000). - Reported six-month revenue ($441,689,000) was higher than the prior-year six-month figure ($370,559,000). - Reported three-month operating result (-$10,666,000) was a loss, while the prior-year three-month operating result (-$22,867,000) was also a loss; the transition remained loss to loss. - Reported six-month operating result (-$27,748,000) was a loss, while the prior-year six-month operating result (-$54,947,000) was also a loss; the transition remained loss to loss. - Reported three-month net income (-$10,592,000) was a loss, with the prior-year three-month net income (-$21,817,000) also a loss; the transition remained loss to loss. - Reported six-month net income (-$26,489,000) was a loss, with the prior-year six-month net income (-$52,287,000) also a loss; the transition remained loss to loss. - Reported three-month diluted earnings per share (-$0.32 per diluted share) was a loss, with the prior-year three-month diluted EPS (-$0.67 per diluted share) also a loss; the transition remained loss to loss. - Reported six-month diluted earnings per share (-$0.8 per diluted share) was a loss, with the prior-year six-month diluted EPS (-$1.61 per diluted share) also a loss; the transition remained loss to loss.

The filing evidence does not attribute this change to any single cause.

This is an interim filing on the same form referenced in the Item 1 through Item 6 sequence, and the unaudited Condensed Consolidated Financial Statements are prepared in accordance with U.S. GAAP for interim financial information following the instructions to Form 10-Q and the cited Regulation S-X article. The condensed consolidated results for the three and six months ended in July are stated by management not to be necessarily indicative of the full-year outcome. The balance sheet position referenced as of January was derived from the previously filed audited Annual Report on Form (omitted) under SEC filing mechanics noted in the source narrative.

Counter-evidence and unknown territory: the filing itself reports forward-looking statements under the cautionary statement in the cited exhibit index, and the proposed Merger context disclosed in the Significant Accounting Policies narrative introduces a pending transaction overlay; neither of these dimensions alters the reported revenue and loss pattern above, but both frame how this interim window should be read. Peer benchmarking is not provided in the filing evidence (The filing evidence contains no peer or industry comparison.), so no cross-issuer comparison can be drawn here. The source narrative also flags that the Company is evaluating the effect of recent ASU guidance on expense disaggregation, internal-use software capitalization, and income-tax disclosures, none of which is quantified in this section.

Source scope for this analysis is limited to the 10-Q interim filing of SILICON LABORATORIES INC. under accession 0001038074-26-000029, the cited Risk Factors, Controls and Procedures, and Legal Proceedings items within Item 1A, Item 2, Item 3, and Item 4, the Other Information and Exhibits items within Item 5 and Item 6, and the fair-value hierarchy tiers within Level 1, Level 2, and Level 3, as applicable to this section. Readers looking for a recent same-form profit-to-profit benchmark can compare the directional pattern to Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows or Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows, which anchor a contrasting interim outcome.

Financial performance

- The filing reports a loss on the bottom line for both the three-month and six-month windows relative to the prior-year comparative periods, with diluted earnings per share of -$0.32 per diluted share and -$0.8 per diluted share against prior-period figures of -$0.67 per diluted share and -$1.61 per diluted share USD/SHARES, respectively, and net income (loss) attributable to parent of -$10,592,000 and -$26,489,000 against prior-period losses of -$21,817,000 and -$52,287,000 USD. - Authorized direction: diluted earnings per share improved on both the quarter and half-year windows, and net loss attributable to parent narrowed on both windows; the authorized transition on each is loss to loss. - Operating income (loss) is also negative for both windows of the current reporting period at -$10,666,000 and -$27,748,000 USD, versus prior-period losses of -$22,867,000 and -$54,947,000 USD; the authorized direction is a narrowing of the operating loss on both windows, with the transition loss to loss. - Revenue from contract with customer, excluding assessed tax, of $228,189,000 and $441,689,000 USD sits against prior-period revenue of $192,845,000 and $370,559,000 USD; the authorized direction is higher than the prior period on both windows, so the top line improved while the bottom line remained negative. - The narrative context frames the condensed results as not necessarily indicative of the full year and notes a (omitted)-week fiscal period with the extra week in the first quarter; readers should weight the period comparability with that in mind. - Accounting estimates flagged as significant cover inventories, goodwill, acquired intangible assets, other long-lived assets, revenue recognition, stock-based compensation, and income taxes, with the filing cautioning that actual results could differ materially. - Recent ASU updates cited in the notes address expense disaggregation disclosures, internal-use software capitalization clarifications, and other narrowly scoped changes, each with effective dates for annual and interim periods beginning after December (omitted); the Company states it is currently evaluating the effect on its consolidated financial statements. - The merger context is conspicuous in the filing — a definitive agreement with a Parent entity and a merger subsidiary under which each share of the Company's common stock would be cancelled and converted into the right to receive (omitted) in cash, with stockholder approval already obtained and closing expected in the first half of (omitted) subject to regulatory approvals, and transaction costs already incurred of (omitted) million for the quarter and (omitted) million for the half-year. - Anti-dilutive securities excluded from diluted EPS were not material for the current periods and totaled (omitted) million shares for the three months and (omitted) million shares for the six months of the prior-year comparative. - Fair-value disclosures rely on a three-level hierarchy, with Level 1 referencing quoted prices in active markets for identical items, Level 2 covering other directly or indirectly observable inputs, and Level 3 reserved for unobservable inputs developed by the Company; the financial-instrument tables exclude cash on hand and items carried at historical cost. - The filing does not provide peer, sector, or industry comparison figures, and the only direction-based comparisons supplied are the reported ones above; any read-across to other semiconductors or analog peers must come from outside this filing. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

LINKS: /insights/finance/reinsurance-group-of-america-inc-posts-higher-revenue-and-net-income-in-period/

Operating drivers and segments

- The interim report from SILICON LABORATORIES INC. (SLAB) for period-ended-2026-07-04 on 10-Q (0001038074-26-000029) does not present product-line or end-market segments in the cited excerpt; the operating picture is condensed to a single consolidated total, so segment-level margin behaviour cannot be read from the filing itself. - Revenue from Contract with Customer, Excluding Assessed Tax moved higher than the prior-year period on both windows: the three-month reporting period the three months ended July 4, 2026 versus the three months ended July 5, 2025, and the six-month year-to-date period the six months ended July 4, 2026 versus the six months ended July 5, 2025. The current-quarter revenue is $228,189,000 and the prior-year quarter is $192,845,000; the half-year revenue is $441,689,000 and the prior-year half-year is $370,559,000. - Operating Income (Loss) also moved higher than the prior-year period on both windows, but it remains a loss on an absolute basis rather than a profit: the three-month reporting period is -$10,666,000 against -$22,867,000, and the six-month year-to-date period is -$27,748,000 against -$54,947,000. The headline movement is therefore a narrower operating loss rather than a return to operating profit. - Because the filing reports only one consolidated operating line, there is no separate gross-margin, segment-margin, or geographic split to weigh against the top-line and operating-line moves.

- Management frames the forward-looking commentary with the customary "believe," "estimate," "expect," "intend," "anticipate," "plan," "project," "will" language and cautions that actual results could differ materially, with risk factors discussed elsewhere in the report (see Item 1A). - The interim financial statements were prepared under U.S. GAAP for interim reporting, with all normal recurring accruals and adjustments that management considers necessary for a fair presentation, and the condensed consolidated results for the three and six months ended in July are flagged as not necessarily indicative of the full year. - Management identifies several significant estimates that affect the financial statements, including inventories, goodwill, acquired intangible assets, other long-lived assets, revenue recognition, stock-based compensation, and income taxes, and notes that actual results could differ from those estimates. - Management is currently evaluating several recent ASUs — on expense disaggregation disclosures, internal-use software, and another referenced update — and has not yet quantified their effect on the consolidated financial statements. - A Proposed Merger context is disclosed: on a February date the Company entered into a Merger Agreement with Texas Instruments Incorporated and Caldwell Merger Corp., the board unanimously approved the transaction, stockholders approved it on an April date, and the Merger is expected to close in the first half of a later year subject to customary closing conditions including required regulatory approvals. Management does not in the cited excerpt separate any operational driver from this pending corporate event. - The filing also notes that fiscal period-ended-2026-07-04 contained a stated number of weeks with the extra week occurring in the first quarter of the year, which is a calendar-structure point rather than an operating-performance driver. - On the operating-line improvement itself, The filing evidence does not attribute this change to any single cause.. - The filing evidence contains no peer or industry comparison, so any read-across to similar semiconductor names cannot be supported from this filing alone: The filing evidence contains no peer or industry comparison.. Readers who want a comparable interim-filing read on a different issuer can look at Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows for context, but that piece covers a different company and does not benchmark SLAB directly.

Cash flow and capital

- Operating cash flow for the six-month year-to-date period described in this 10-Q filing from SILICON LABORATORIES INC. (SLAB, CIK 0001038074, accession 0001038074-26-000029, period-ended-2026-07-04) was a use of cash of -$9,578,000 USD, a directional shift from the prior-year six-month year-to-date period when operating cash flow was a source of $53,036,000 USD. The cash-flow statement therefore moved from cash generation to cash consumption at the operating line, while reported net income for the same period was a loss against a prior-year loss, The filing evidence does not attribute this change to any single cause..

- Investing activities provided $27,238,000 USD over the six-month year-to-date period, compared with a use of -$14,051,000 USD in the prior-year six-month window, a swing from a use of cash to a source of cash. Capital expenditures rose to $22,153,000 USD from $13,549,000 USD in the prior-year half-year period, indicating higher spending on property, plant, and equipment alongside the broader shift in the investing line. The filing evidence does not attribute this change to any single cause..

- Financing activities used -$19,691,000 USD in the current six-month year-to-date period, a larger use of cash than the prior-year six-month period when financing used -$6,133,000 USD, with management attributing cash deployment during the period to the costs of the proposed Merger described elsewhere in this Earnings Analysis; the filing evidence does not separate routine financing items from deal-related outflows, and The filing evidence does not attribute this change to any single cause.. - On the balance sheet as of the balance sheet date of July 4, 2026, cash and cash equivalents stood at $362,191,000 USD, with accounts receivable of $79,801,000 USD and accounts payable of $52,407,000 USD.

The filing records accounts receivable and accounts payable at amounts approximating fair value because of their short maturities, and unobservable Level 3 inputs are not used to value these short-tenor working-capital balances. - Capital allocation is currently dominated by the pending transaction with Parent, under which each public share will be converted into the right to receive cash consideration and the Company will become a wholly-owned subsidiary of Parent, with the Merger expected to close in the first half of the next calendar year subject to customary regulatory approvals.

The board has already obtained the required stockholder approval, and the resulting cash settlement implies that ongoing share repurchase or dividend programs are not described as continuing capital-allocation priorities in this section. Merger-related costs already incurred for the three and six months ended July of the current fiscal year are noted in the narrative, but the company does not break out a separate deal-cost cash line in the summarized statement of cash flows. - The combined pattern of negative operating cash flow, higher investing activity, and a larger financing use is consistent with a company funding both elevated capital expenditures and Merger-related outflows from its cash and short-term investment balances, rather than from internally generated cash, and the filing evidence does not attribute this combined pattern to any single cause.

For readers who want a recent comparable profile of an interim filing, the REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in the reporting period Filing piece illustrates a contrasting operating-cash-flow direction across the same kind of report.

Peer and historical context

The comparison set for SILICON LABORATORIES INC. under 10-Q period-ended-2026-07-04 is narrower than the headline figures suggest. The filing presents the the six months ended July 4, 2026 and the three months ended July 4, 2026 windows alongside their prior-year counterparts (the six months ended July 5, 2025 and the three months ended July 5, 2025) drawn from the same internal periods, so the only like-for-like frame the document supports is a year-over-year read on SLAB's own historical results. The filing evidence contains no peer or industry comparison, so any cross-issuer frame has to be sourced elsewhere.

- Year-over-year, top line moved higher on both windows. Revenue from Contract with Customer, Excluding Assessed Tax for the the six months ended July 4, 2026 sits above the the six months ended July 5, 2025 comparative, and the same directional read applies to the the three months ended July 4, 2026 versus the three months ended July 5, 2025, a profit-to-profit-growth pattern that the reader can contrast with the parallel cases shown in the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing write-up. - Profitability did not keep pace with that revenue direction. Operating Income (Loss) for the the six months ended July 4, 2026 is a larger loss than the the six months ended July 5, 2025 comparative, and the the three months ended July 4, 2026 operating loss is also wider than the the three months ended July 5, 2025 reading. Net Income (Loss) Attributable to Parent mirrors that gap on both windows: the the six months ended July 4, 2026 loss is larger than the the six months ended July 5, 2025 loss, and the the three months ended July 4, 2026 loss is wider than the the three months ended July 5, 2025 loss. - On a per-share basis, Earnings Per Share, Diluted registers the same authorized transition loss to loss on each window, with the authorized direction being an increase on both the the six months ended July 4, 2026 against the six months ended July 5, 2025 and the the three months ended July 4, 2026 against the three months ended July 5, 2025. - Cash generation tells a different story than earnings. Net Cash Provided by (Used in) Operating Activities for the the six months ended July 4, 2026 swung from positive in the the six months ended July 5, 2025 to negative in the the six months ended July 4, 2026, an authorized decrease. The Investing and Financing flows are also signed and directed, with Net Cash Provided by (Used in) Investing Activities moving from negative in the the six months ended July 5, 2025 to positive in the the six months ended July 4, 2026, and Net Cash Provided by (Used in) Financing Activities remaining negative on both sides of the comparison with an authorized decrease. Payments to Acquire Property, Plant, and Equipment rose from the the six months ended July 5, 2025 to the the six months ended July 4, 2026, an authorized increase on the capex line. - The narrative material on derivative hedging, the credit-facility covenants (consolidated net leverage ratio and minimum interest coverage ratio), and the litigation footnote in Item 1 and the controls discussion in Item 4 do not speak directly to the year-over-year gap between revenue growth and the wider loss; they describe the surrounding risk and disclosure environment only.

The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison.

Scenario analysis

The base reading of the 10-Q filed by SILICON LABORATORIES INC. (SLAB) under accession 0001038074-26-000029 for the period-ended-2026-07-04 spans two reported windows: the three months ended July 4, 2026 and the six months ended July 4, 2026. In both, Revenue from Contract with Customer, Excluding Assessed Tax rose versus the prior-year comparative periods (the three months ended July 5, 2025 and the six months ended July 5, 2025), with the three-month period at $228,189,000 USD and the six-month period at $441,689,000 USD. The earnings line in both windows stayed in a loss posture, with Net Income (Loss) Attributable to Parent at -$10,592,000 USD for the three months ended July 4, 2026 and -$26,489,000 USD for the six months ended July 4, 2026, against the prior-year losses of -$21,817,000 USD and -$52,287,000 USD. The transitions are loss-to-loss, so the upside vs downside split hinges on whether incremental revenue reaches the bottom line.

Revenue continuing to scale quarter-over-quarter and year-over-year, alongside any narrowing in the gap to break-even on earnings, would frame an upside view. Given that revenue in both windows increased while the net result remained a loss, the upside case rests on the earlier losses moderating rather than on a profit inflection at this filing. The filing evidence does not attribute this change to any single cause.

A downside reading concentrates on the persistence of the loss on both lines — quarterly and half-year — even as topline grew. If incremental revenue does not translate into narrower losses in subsequent periods, the trajectory remains loss-to-loss and could compress margins further. The filing evidence does not attribute this change to any single cause. Tail-risk color in the filing itself points to covenant sensitivity under the credit facility (consolidated net leverage and minimum interest coverage ratios), and to non-material fair-value movements on foreign currency forward contracts whose gains/losses sit in interest income and other, net; litigation referenced under Item 1 is described by management as not expected to have a material adverse effect, so this is monitoring-grade rather than thesis-breaking.

Counter-evidence and unknowns: - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension. - The cited Item 1A reference window lists risk factors and unregistered sales, but no segment-level color is provided here. - Fair-value disclosures sit under the Level 1, Level 2, and Level 3 hierarchy references; for the scenarios above, levels are cited as structure, not as numeric anchors. - Item 4 (Controls and Procedures) and Item 3 (Quantitative and Qualitative Disclosures About Market Risk) shape operational and market-risk framing without altering the scenario calculus. - Item 6 carries the cautionary-statement language that historical performance is not a guarantee of future results, which tempers both upside and downside. - Stock-based compensation continues to be expensed, with fair values for options and ESPP rights estimated using the Black-Scholes model per the cited note.

Read alongside the Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows note, where a similar loss-to-loss transition was framed differently, the contrast reinforces that this section is anchored strictly to the loss-to-loss posture disclosed here.

LINKS: [/insights/finance/lizely-finance-earnings-analysis-ani-pharmaceuticals-interim-filing-profit-to/]

Risks and what to watch

- Reported facts The filing under 10-Q period-ended-2026-07-04 (0001038074-26-000029), filed by SILICON LABORATORIES INC. (SLAB, CIK 0001038074), records a net loss attributable to parent for both the three-month and six-month windows. Current period figures came in at -$10,592,000 for the quarter and -$26,489,000 for the year-to-date, both losses.

The matching prior-year comparables were also losses, at -$21,817,000 for the quarter and -$52,287,000 for the six-month window. Revenue, however, was positive on every window: $228,189,000 for the current quarter, $441,689,000 for the current six-month period, $192,845,000 for the prior-year quarter, and $370,559,000 for the prior-year half-year. The authorized transitions are loss-to-loss on both earnings windows, with the year-over-year direction stated as an increase, while revenue moved in the authorized increase direction on both windows.

- Management explanations Management frames foreign-currency forward contracts as immaterial and discloses that the credit facility, apart from swingline loans, is priced off an Adjusted Term SOFR-based rate with a base-rate option. The facility is supported by guarantees from the listed Guarantors and a security interest in substantially all assets, and the disclosure notes compliance with the consolidated net leverage ratio and the minimum interest coverage ratio covenants as of the cited date. The revenue discussion groups the catalog as Industrial & Commercial or Home & Life, with performance-obligation catch-up figures called out for the current three- and six-month windows and described as insignificant for the prior-year comparables.

Stock-based compensation is summarized in terms of grant-date fair value, intrinsic-value treatment for awards, and Black-Scholes valuation for options and ESPP rights. - Analyst inference Drawing on the authorized relations only, the picture is one of higher revenue paired with a continuing loss on both windows, so the prior-year loss has narrowed rather than flipped. The covenant compliance language and the secured-debt structure are the most direct risk mitigants highlighted, while the loss-to-loss earnings transition is the most direct profitability flag.

The grouping of products by target market is a non-financial structural cue that does not, by itself, alter the financial read. - Counter-evidence No counter-evidence is presented within the filing evidence; the filing does not introduce a separate opposing data stream. The contrast the reader can lean on is internal: positive revenue against a loss result on the same windows.

- Unknowns The filing evidence does not provide peer or industry comparison data, so cross-company context is unavailable. Segment-level revenue detail is not disclosed, and the filing does not attribute the year-over-year movements to any single cause. A reader looking to benchmark SILICON LABORATORIES INC.

against similar interim filers can browse UFP TECHNOLOGIES INC Interim Filing coverage for a profit-to-profit comparison window and ANI Pharmaceuticals Interim Filing coverage for a related profit-to-profit read. - Metrics to watch next period Revenue trend on both the three-month and six-month windows, the loss result on those same windows, covenant headroom under the credit facility, and the relative weight of Industrial & Commercial versus Home & Life revenue as the grouping is disclosed again next period.